Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients.
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
11
2019
revised:
02
02
2020
accepted:
18
02
2020
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
17
12
2020
Statut:
epublish
Résumé
Hyperhomocysteinemia plays a crucial role in the pathogenesis of many diseases of the central nervous system (CNS). The nervous system is particularly sensitive to high homocysteine (Hcy) level mainly due to its prooxidative and cytotoxic effects. Cladribine, a drug recently registered for the treatment of multiple sclerosis (MS), possesses additionally neuroprotective effects which are independent of its peripheral immunosuppressant action. Accumulating evidence suggests that oxidative stress and homocysteine thiolactone-mediated protein homocysteinylation play a causal role in MS. Both of these processes may be attenuated by paraoxonase 1 (PON1). Therefore, in the present study, we aimed to examine whether the beneficial effects of the drug in MS patients with a secondary progressive (SP) clinical course, treated with cladribine subcutaneously (s.c.), may be related to its ability to modify serum PON1 activity, Hcy concentration, and protein homocysteinylation, as well as to correct total antioxidant status. A total of 118 subjects were enrolled into the study: (1) patients with a SP type of MS, SP-MS (
Identifiants
pubmed: 32256946
doi: 10.1155/2020/1654754
pmc: PMC7103043
doi:
Substances chimiques
Antineoplastic Agents
0
Antioxidants
0
Cladribine
47M74X9YT5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1654754Informations de copyright
Copyright © 2020 Anna Jamroz-Wiśniewska et al.
Déclaration de conflit d'intérêts
The authors declare no financial or other conflicts of interest.
Références
J Neuroimmunol. 2013 Nov 15;264(1-2):8-13
pubmed: 24045165
CNS Neurol Disord Drug Targets. 2017;16(4):484-491
pubmed: 28240188
J Neurosci Res. 2002 Dec 1;70(5):694-702
pubmed: 12424737
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Lancet. 1994 Jul 2;344(8914):9-13
pubmed: 7912347
Expert Opin Pharmacother. 2017 Oct;18(15):1627-1635
pubmed: 28858531
Mult Scler Relat Disord. 2019 Jan;27:117-120
pubmed: 30368223
Dis Markers. 2013;34(5):341-8
pubmed: 23478275
J Clin Neurosci. 2011 Jul;18(7):933-8
pubmed: 21570300
J Neurol. 2008 Jan;255(1):64-9
pubmed: 18080853
J Biol Chem. 2000 Feb 11;275(6):3957-62
pubmed: 10660550
Atherosclerosis. 2006 Jul;187(1):74-81
pubmed: 16229851
J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):189-92
pubmed: 16421120
J Clin Neurosci. 2013 Aug;20(8):1106-9
pubmed: 23669169
Anal Biochem. 1996 Jul 15;239(1):70-6
pubmed: 8660627
Am J Hematol. 2015 Jan;90(1):62-72
pubmed: 25284482
Leuk Lymphoma. 2009 Oct;50 Suppl 1:12-7
pubmed: 19814692
Int J Neurosci. 2017 Aug;127(8):709-715
pubmed: 27671515
Mult Scler Relat Disord. 2017 Oct;17:190-197
pubmed: 29055456
Biochim Biophys Acta. 2005 Sep 15;1725(2):213-21
pubmed: 16112460
Mult Scler. 2011 May;17(5):578-93
pubmed: 21228029
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Nephrol Dial Transplant. 2007 Jun;22(6):1685-9
pubmed: 17317712
N Engl J Med. 2010 Feb 4;362(5):416-26
pubmed: 20089960
Oxid Med Cell Longev. 2015;2015:725370
pubmed: 26106458
Mult Scler. 2007 May;13(4):446-53
pubmed: 17463067
J Endocrinol. 2010 Feb;204(2):191-8
pubmed: 19887391
Arterioscler Thromb Vasc Biol. 1999 Feb;19(2):330-5
pubmed: 9974415